---
schema_version: "secwatch.filing_event.v1"
accession: "0000950142-21-003244"
form_type: "8-K"
ticker: "VTVT"
cik: "0001641489"
company_name: "vTv Therapeutics Inc."
filed_at: "2021-10-20T23:59:59+00:00"
generated_at: "2026-06-28T19:40:20.539150+00:00"
event_type: "leadership"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# vTv Therapeutics appoints Deepa Prasad as President and CEO; Holcombe retires

## Summary
- Stephen Holcombe retired as CEO effective Oct 19, 2021; will serve as Strategic Advisor for one year, receiving $450k/yr severance through Dec 2022.
- Deepa Prasad appointed President & CEO; base salary $650k, 100% bonus, options for 2,498,635 shares at $1.47.
- Prasad brings 20+ years healthcare experience; was Managing Director at WestRiver Group, led investments in DSGN, Ginger, Curai.
- Company to launch Phase 3 pivotal studies for TTP399, a Type 1 diabetes treatment with FDA Breakthrough Therapy Designation.
- TTP399 Phase 2 showed significant HbA1c improvement and 40% reduction in symptomatic hypoglycemia vs placebo.

## SEC filing metadata
- accession: 0000950142-21-003244
- form_type: 8-K
- ticker: VTVT
- cik: 0001641489
- company_name: vTv Therapeutics Inc.
- filed_at: 2021-10-20T23:59:59+00:00
- event_type: leadership
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1641489/000095014221003244/0000950142-21-003244-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1641489/000095014221003244/eh210193502_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950142-21-003244
- JSON: https://secwatch.observer/filing/0000950142-21-003244.json
- Plain text: https://secwatch.observer/filing/0000950142-21-003244.txt

## Key facts
- Executive change
  Deepa Prasad was appointed as President and Chief Executive Officer at vTv Therapeutics Inc..
  - Action: appointed
  - Role: President and Chief Executive Officer
  source text: On the Effective Date, the Company announced that the Board has appointed Deepa Prasad as President and Chief Executive Officer and as a member of the Board.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1641489/000095014221003244/0000950142-21-003244-index.htm
- Executive change
  Stephen Holcombe retired as Chief Executive Officer at vTv Therapeutics Inc..
  - Action: retired
  - Role: Chief Executive Officer
  source text: On October 19, 2021, (the “Effective Date”) Stephen Holcombe announced his retirement as Chief Executive Officer and as an employee of vTv Therapeutics Inc. (the “Company”), effective as of the Effective Date.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1641489/000095014221003244/0000950142-21-003244-index.htm
- Executive change
  Deepa Prasad was appointed as Director at vTv Therapeutics Inc..
  - Action: appointed
  - Role: Director
  source text: On the Effective Date, the Company announced that the Board has appointed Deepa Prasad as President and Chief Executive Officer and as a member of the Board.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1641489/000095014221003244/0000950142-21-003244-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.